보고서 요약(국문)

시장 개요
세계 녹내장 치료제 시장은 2022년 61억 달러 규모에 도달했으며, 2030년까지 93억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 세계 녹내장 치료제 시장은 예측 기간(2023~2030년) 동안 연평균 5.7%의 성장률을 기록할 것으로 예상됩니다. 기술 발전과 신약 개발을 위한 임상 시험 증가가 녹내장 치료제 시장 수요 증가를 견인하고 있습니다.
혁신적인 약물 전달 시스템 개발, 새로운 약물 조합 출시, 그리고 녹내장 환자 수 증가는 세계 녹내장 치료제 시장 성장을 이끄는 주요 요인입니다.
녹내장 치료제 시장은 개방각 녹내장, 폐쇄각 녹내장, 선천성 녹내장, 이차성 녹내장 등 다양한 유형의 녹내장을 포괄하며, 이는 시장 점유율 증가에 기여하고 있습니다. 녹내장 치료제 시장은 연구 개발 증가와 각국의 신약 승인 예정 등 여러 요인으로 인해 확대되고 있으며, 이는 녹내장 치료제 시장 성장에 긍정적인 전망을 제시하고 있습니다.
시장 동향
주요 기업들의 임상 시험 증가가 녹내장 치료제 시장 성장을 견인
지난 30년간 녹내장 연구를 위한 임상 연구 건수는 상당히 증가했습니다. 녹내장 치료법 개선을 위해 전 세계적으로 수많은 연구가 진행되고 있으며, 특히 수술, 약물, 행동 치료를 연구하는 임상 시험이 주목받고 있습니다. 임상 시험은 특정 치료법을 시험하고, 약물의 적정 용량을 결정하며, 치료의 부작용을 평가하는 네 단계로 진행됩니다.
최근 평가된 물질들에는 세 가지 주요 치료법이 모두 포함되어 있지만, 혈관 및 신경 보호 치료법에 대한 임상 시험은 아직 미미한 수준입니다. 기존 약물 치료 외에도 영양 보충제와 성장 호르몬의 항녹내장 효과에 대한 연구가 진행되고 있습니다.
모든 질환 및 안과 질환 전반에 걸쳐 2상 및 3상 임상시험의 성공률은 이전에 보고된 성공률보다 낮았습니다. 녹내장 또는 안과 연구에서 개인별 표현형을 더욱 엄격하게 분류하면 성공률을 높이고 연구자들이 반응자와 비반응자를 식별하는 데 도움이 될 수 있습니다.
연구 개발 및 신제품 출시 증가로 제조업체에 수익성 높은 기회가 창출되고 있습니다.
수많은 연구원과 연구원들이 임상 연구 및 기초 과학 연구에 기여함으로써 새로운 치료법 개발이 가속화되었고 질환의 발생 원인과 경과에 대한 이해가 크게 향상되었습니다. 여러 임상시험이 진행 중이며 긍정적인 결과가 나오고 있습니다.
신제품 출시 증가와 규제 승인은 녹내장 치료제 시장 성장의 주요 동력입니다. 예를 들어, 2022년 9월 22일, 산텐과 UBE는 원발성 개방각 녹내장 또는 안압항진증 환자의 과도한 안압을 낮추는 데 사용되는 옴론티 0.002% 점안액에 대해 FDA 승인을 발표했습니다.
옴론티의 활성 의약 성분인 오미데네팍 이소프로필은 이러한 특정한 약리학적 작용을 하는 유일한 약물입니다. 이는 프로스타글란딘 EP2 수용체 작용제로, 기존 유출 경로와 포도막공막 유출 경로를 통해 방수 배출을 증가시킵니다.
약물 관련 부작용이 시장 성장을 저해할 것입니다.
녹내장 치료제의 잠재적인 부작용은 다양합니다. 눈 색깔 변화, 눈꺼풀 피부 착색, 속눈썹 성장, 눈꺼풀 함몰, 눈꺼풀 처짐, 따끔거림, 충혈, 가려움증은 모두 프로스타글란딘 유사체의 징후입니다. 베타 차단제는 때때로 서혈압, 서맥, 피로, 호흡 곤란을 유발할 수 있습니다. 매우 드물게 우울증과 성욕 감퇴를 유발하기도 합니다.
작열감이나 따끔거림, 피로, 두통, 졸음, 구강 건조, 코 건조, 그리고 알레르기 반응 발생 가능성 증가는 모두 알파 작용제의 가능한 부작용입니다. 경구용 탄산무수효소 억제제는 손발 저림, 피로, 위장 장애, 기억력 문제, 빈뇨를 유발할 수 있습니다. 점안액 형태는 따끔거림, 작열감, 안구 통증을 유발합니다.
COVID-19 영향 분석
전 세계 여러 국가의 COVID-19 팬데믹과 봉쇄 조치로 인해 모든 산업 분야 기업의 재정 건전성이 영향을 받았습니다. 따라서 COVID-19 보건 비상 사태 기간 동안 미국 식품의약국(FDA)은 임상시험 참여자의 안전을 보장하고, 임상시험 관리 기준(GCP)을 준수하며, 임상시험의 무결성에 대한 위험을 최소화하는 등 스폰서와 연구자를 지원하기 위한 일반적인 고려 사항을 포함하는 지침을 발표했습니다.

러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 녹내장 치료제 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재 수출입은 예측 기간 동안 전 세계 녹내장 치료제 시장 성장에 거의 영향을 미치지 않을 것으로 전망됩니다.
시장 세분화 분석
전 세계 녹내장 치료제 시장은 녹내장 유형, 약물 유형, 유통 채널 및 지역별로 세분화됩니다.
약물 유형별 시장 점유율 36.7%를 차지하는 프로스타글란딘 제제는 사용량 증가에 힘입어 시장을 주도하고 있습니다.
처방 안약은 녹내장 치료에 가장 일반적으로 사용되는 약물입니다. 안약은 안압을 낮추고 시신경을 보호하는 역할을 합니다. 이러한 안약은 시력 손실을 회복시키거나 녹내장을 완치하는 것은 아니지만, 녹내장의 악화를 예방할 수 있습니다.
녹내장 치료에는 다양한 약물이 사용 가능합니다. Xalatan(라타노프로스트), Travatan Z(트라보프로스트), Lumigan(비마토프로스트), Zioptan(타플루프로스트), Vyzulta(라타노프로스테네 부노드)는 눈에서 체액의 배출을 촉진하는 프로스타글란딘 유사체(PGA)의 예입니다.
효과적이고 1일 1회 복용이 가능하며 부작용이 거의 없기 때문에 프로스타글란딘 유사체(PGA)는 녹내장 치료의 핵심으로 여겨집니다. 모든 수술적 및 약물적 녹내장 치료의 주요 목표는 안압(IOP)을 낮추는 것이며, 현재 안압은 유일하게 조절 가능한 요소입니다.
지역 분석
북미는 주요 업체들의 강력한 입지와 기술 발전으로 인해 시장 점유율의 약 39.9%를 차지했습니다.
북미에서 녹내장 치료제에 대한 수요가 증가함에 따라 제조업체들은 이 지역에서 사업을 확장할 기회를 얻고 있습니다. 이 지역에는 많은 생산자와 공급업체가 있으며, 빠른 경제 발전으로 녹내장 치료제 산업 생산이 증가하여 수요가 늘어났습니다. 북미에는 많은 제조업체와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 인해 산업 생산이 확대되었습니다.
기술 발전, 정부 승인, 신제품 출시 등이 모두 성장에 기여하고 있습니다. 사람들은 시력 관련 질환과 새로운 기술에 대한 인식이 높아지고 있으며, 이는 이 지역 시장의 확대를 이끌고 있습니다. 이러한 요인들은 북미 시장의 지배력을 보여줍니다.
경쟁 환경
녹내장 치료제 시장의 주요 글로벌 기업으로는 Merck & Co., Inc., AbbVie Inc., Pfizer Inc., Alcon, Novartis AG, Bausch & Lomb, Inotek Pharmaceuticals, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Vivavision Biotech Ltd. 등이 있습니다.
보고서 구매 이유

• 녹내장 유형, 약물 유형, 유통 채널 및 지역별 글로벌 녹내장 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 녹내장 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 녹내장 치료제 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Glaucoma Therapeutics Market reached US$ 6.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 9.3 billion by 2030. The global glaucoma therapeutics market is expected to exhibit a CAGR of 5.7% during the forecast period (2023-2030). The increasing technological advancements and the growing clinical trials for novel products are driving up demand for glaucoma therapeutics market trends.
The development of innovative drug delivery systems, the launch of new drug combinations, and an increase in patients with glaucoma are the main factors propelling the global market for glaucoma therapeutics.
The glaucoma therapeutics market scope comprises glaucoma type as open angle glaucoma, angle-closure glaucoma, congenital glaucoma and secondary glaucoma, which has increased the glaucoma therapeutics market share. The global market for glaucoma therapeutic is expanding as a result of factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the glaucoma therapeutics market growth.
Market Dynamics
The Rising Clinical Trials by Key Companies Drive the Growth of the Glaucoma Therapeutics Market
Over the past 30 years, there has been a considerable increase in the number of clinical studies for glaucoma research. In order to improve glaucoma treatment, numerous studies are being carried out globally to study the illness. Clinical trials examining either surgical, medicinal, or behavioral intervention are particularly intriguing among these. Clinical trials progress over four phases that test a specific treatment, determine the right dosage of a certain drug, and assess the treatment's negative effects.
All three major treatment modalities were present among the most recently assessed substances, but there are still few clinical trials in vascular and neuroprotection modalities. In addition to conventional medications, the possible anti-glaucomatous effects of nutritional supplements and growth hormones are investigated.
For all disorders and ophthalmology in general, phase II and phase III success rates were lower than previously stated success rates. In glaucoma or ophthalmological research, stricter phenotyping for individuals can increase success rates and help researchers identify responders and non-responders.
Rising Research and Development and Novel Product Launches Creates Lucrative Opportunities for Manufacturers
Contributions to clinical research and fundamental science research from a number of researchers or fellows have accelerated the development of novel treatments and significantly improved our understanding of the origins and course of disorders. Several clinical trials are being conducted resulting in positive outcomes.
The rising novel product launches and regulatory approvals are the key driving factors for the growth of the glaucoma therapeutics market. For instance, on September 22, 2022, FDA approval of Omlonti 0.002% eye drops for lowering excessive IOP in people with primary open-angle glaucoma or ocular hypertension was announced by Santen and UBE.
Omlonti's active pharmaceutical ingredient, omidenepag isopropyl, is the only medication with this specific pharmacological action. It is a prostaglandin EP2 receptor agonist that increases aqueous humor drainage through the traditional and uveoscleral outflow pathways.
Side Effects Linked with Drugs Will Hamper the Growth of the Market
The potential adverse effects of glaucoma medicines are varied. Eye color changes, eyelid skin darkening, eyelash growth, sunken eyes, droopy eyelids, stinging, redness, and itching are all signs of prostaglandin analogues. Beta blockers occasionally cause slow blood pressure, a slower heartbeat, weariness, and shortness of breath; very rarely, they also cause depression and a decreased libido.
Burning or stinging, exhaustion, headaches, drowsiness, dry mouth, dry nose, and a substantially greater chance of allergic reaction are all possible effects of alpha agonists. When used as pills, carbonic anhydrase inhibitors can induce tingling in the hands and feet, weariness, stomach trouble, memory issues, and frequent urination. Eye drop form produces stinging, burning, and eye pain.
COVID-19 Impact Analysis
The financial health of companies across all industries has been impacted by the COVID 19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the interval of the COVID-19 health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global glaucoma therapeutic market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global glaucoma therapeutics market growth over the forecast period.
Segment Analysis
The global glaucoma therapeutics market is segmented based on glaucoma type, drug type, distribution channel and region.
Prostaglandins from Drug Type Segment Account for 36.7% of the Market Share Owing to Rising Utilization
Prescription eye drops are the most typical form of treatment for glaucoma. These work by lowering intraocular pressure and safeguarding the optic nerve. These eye drops won't restore vision loss or treat glaucoma, but they can prevent it from growing worse.
To treat glaucoma, a variety of medications are available. Xalatan (latanoprost), Travatan Z (travoprost), Lumigan (bimatoprost), Zioptan (tafluprost), and Vyzulta (latanoprostene bunod) are examples of prostaglandin analogs that operate by enhancing the outflow of fluid from the eye.
Due to their effectiveness, once-daily dose, and minimal side effect profile, prostaglandin analogs (PGAs) are considered the cornerstone of glaucoma treatment. All surgical and medicinal glaucoma treatments have as their primary goal lowering intraocular pressure (IOP), which is now the only adjustable component.
Geographical Analysis
North America Accounted for Approximately 39.9% of the Market Share Owing to the Strong Presence of Major Players and Rising Technological Advancements
Manufacturers have chances to expand their operations in this region because of the rising demand for glaucoma therapeutic advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of glaucoma therapeutic, which has increased the demand. There are many manufacturers and suppliers in North America, and as a result of the region's rapid economic growth, industrial production has expanded.
Rising technological developments, governmental approvals, and the introduction of new products all contribute to growth. People are becoming more aware of novel technologies and disorders related to the eye sight, leading to the expansion of the market in this region. These factors shows the dominance of North America.
Competitive Landscape
The major global players in the glaucoma therapeutics market include Merck & Co., Inc., AbbVie Inc., Pfizer Inc., Alcon, Novartis AG, Bausch & Lomb, Inotek Pharmaceuticals, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd. and Vivavision Biotech Ltd. among others.
Why Purchase the Report?
• To visualize the global glaucoma therapeutics market segmentation based on glaucoma type, drug type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of glaucoma therapeutics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global glaucoma therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Glaucoma Type
3.2. Snippet by Drug Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Rising Clinical Trials by Key Companies
4.1.1.2. Increased Government Support and Initiatives
4.1.2. Restraints
4.1.2.1. Side Effects Linked with Drugs
4.1.3. Opportunity
4.1.3.1. Rising Research and Development and Novel Product Launches
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Glaucoma Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Glaucoma Type
7.1.2. Market Attractiveness Index, By Glaucoma Type
7.2. Open Angle Glaucoma *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Angle-Closure Glaucoma
7.4. Congenital Glaucoma
7.5. Secondary Glaucoma
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Prostaglandins *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Xalatan (latanoprost)
8.2.4. Travatan Z (travoprost)
8.2.5. Zioptan (tafluprost)
8.2.6. Lumigan (bimatoprost)
8.3. Alpha-Adrenergic Agonists
8.4. Beta Blockers
8.5. Carbonic Anhydrase Inhibitors
8.6. Cholinergic Agents
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Glaucoma Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Glaucoma Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Glaucoma Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Glaucoma Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Glaucoma Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck & Co., Inc. *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer Inc.
12.3. AbbVie Inc.
12.4. Alcon
12.5. Bausch & Lomb
12.6. Novartis AG
12.7. Inotek Pharmaceuticals
12.8. Sun Pharmaceutical Industries Ltd.
12.9. Astellas Pharma Inc.
12.10. Vivavision Biotech Ltd.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck & Co., Inc., 4.	Key Developments, Pfizer Inc., AbbVie Inc., Alcon, Bausch & Lomb, Novartis AG, Inotek Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Astellas Pharma Inc., Vivavision Biotech Ltd.

표 목록 (Tables)

List of Tables Table 1 Global Glaucoma Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Glaucoma Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Glaucoma Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Glaucoma Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Glaucoma Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Glaucoma Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)

Table 7 Global Glaucoma Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Glaucoma Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 9 Global Glaucoma Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Glaucoma Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Glaucoma Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Glaucoma Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Glaucoma Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)

Table 14 North America Glaucoma Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 15 North America Glaucoma Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Glaucoma Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Glaucoma Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)

Table 18 Europe Glaucoma Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 19 Europe Glaucoma Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Glaucoma Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Glaucoma Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Glaucoma Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Glaucoma Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Glaucoma Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Glaucoma Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)

Table 26 South America Glaucoma Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 27 South America Glaucoma Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Glaucoma Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Glaucoma Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Glaucoma Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Glaucoma Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Glaucoma Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 AbbVie: Overview

Table 34 AbbVie: Product Portfolio

Table 35 AbbVie: Key Developments

Table 36 Viatris Inc.: Overview

Table 37 Viatris Inc.: Product Portfolio

Table 38 Viatris Inc.: Key Developments

Table 39 Thea Pharma Inc.: Overview

Table 40 Thea Pharma Inc.: Product Portfolio

Table 41 Thea Pharma Inc.: Key Developments

Table 42 Novartis AG: Overview

Table 43 Novartis AG: Product Portfolio

Table 44 Novartis AG: Key Developments

Table 45 Bausch + Lomb: Overview

Table 46 Bausch + Lomb: Product Portfolio

Table 47 Bausch + Lomb: Key Developments

Table 48 MERCK & CO., Inc.: Overview

Table 49 MERCK & CO., Inc.: Product Portfolio

Table 50 MERCK & CO., Inc.: Key Developments

Table 51 Alcon Inc.: Overview

Table 52 Alcon Inc.: Product Portfolio

Table 53 Alcon Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Glaucoma Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)

Figure 3 Global Glaucoma Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 4 Global Glaucoma Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Glaucoma Therapeutics Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Glaucoma Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)

Figure 7 Primary Glaucomas Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 8 Secondary Glaucomas Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 9 Global Glaucoma Therapeutics Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 10 Prostaglandins Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 11 Alpha-Adrenergic Agonists Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 12 Beta Blockers Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 13 Carbonic Anhydrase Inhibitors Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 14 Miotics (Cholinergic Agents) Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 15 Rho Kinase (ROCK) Inhibitors Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 16 Others Drug Class in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 17 Global Glaucoma Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 18 Hospital Pharmacies Distribution Channel in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 19 Retail Pharmacies Distribution Channel in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 20 Online Pharmacies Distribution Channel in Global Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 21 Global Glaucoma Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 22 North America Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 23 North America Glaucoma Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)

Figure 24 North America Glaucoma Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 25 North America Glaucoma Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 26 North America Glaucoma Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 27 Europe Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 28 Europe Glaucoma Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)

Figure 29 Europe Glaucoma Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 30 Europe Glaucoma Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 31 Europe Glaucoma Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 32 Asia-Pacific Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 33 Asia-Pacific Glaucoma Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)

Figure 34 Asia-Pacific Glaucoma Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 35 Asia-Pacific Glaucoma Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 36 Asia-Pacific Glaucoma Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 37 South America Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 38 South America Glaucoma Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)

Figure 39 South America Glaucoma Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 40 South America Glaucoma Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 41 South America Glaucoma Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 42 Middle East and Africa Glaucoma Therapeutics Market Value, 2022-2033 (US$ Billion)

Figure 43 Middle East and Africa Glaucoma Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)

Figure 44 Middle East and Africa Glaucoma Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 45 Middle East and Africa Glaucoma Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 46 AbbVie: Financials

Figure 47 Viatris Inc.: Financials

Figure 48 Thea Pharma Inc.: Financials

Figure 49 Novartis AG: Financials

Figure 50 Bausch + Lomb: Financials

Figure 51 MERCK & CO., Inc.: Financials

Figure 52 Alcon Inc.: Financials

세계 녹내장 치료제 시장 – 2023-2030

Global Glaucoma Therapeutics Market - 2023-2030